Skip to main content
. 2022 Nov 20;25(11):803–810. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2022.102.47

表 3.

178例免疫治疗NSCLC患者LIPI、iSEND免疫评分与mPFS的关系

Relationship between LIPI, iSEND immune score and mPFS in 178 treated with immunotherapy NSCLC patients

Predictive models Group n mPFS (mon) 95%CI
NSCLC: non-small cell lung cancer; mPFS: median PFS.
LIPI Good 56 9.9 8.453-11.247
Intermediate 76 6.1 4.408-7.792
Poor 46 3.7 2.738-4.687
iSEND Good 26 9.9 7.760-11.940
Intermediate 119 7.0 5.716-8.280
Poor 33 3.5 2.583-4.382
Total 178 6.4 5.425-7.454